ClinicalTrials.gg
RecruitingNCT05482321Updated May 6, 2026

Pancreas Ultrasound Imaging in type1 Diabetes

An observational study in Type1diabetes, Insulitis and Pancreas Inflamed, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Colorado, Denver · Observational

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Pancreatitis with a site in United States — 44 open to participants now, 49 under way, 2 of them phase 3. Pancreatitis · United States.

Planned enrollment
33rd of 41
50 · median 433
Started
2023
with 9 others
Observational
42 of 139
15 open now
Primary completion
2026-09
later than 9 of 48 live
Registered
106th of 139
by date

Among the 139 studies in Pancreatitis with a site in United States, this one is the 33rd largest by planned enrollment of the 41 observational ones that give a count, is one of 10 that started in 2023, is one of 42 observational ones, reaches primary completion later than 9 of the 48 other live ones, and was the 106th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

44 of the 139 studies in Pancreatitis with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Pancreatitis with a site in United States, or all of them as a file.
02

Study summary

The overall goal of this study is to develop and test a novel method involving ultrasound imaging, in order to detect the development of type 1 diabetes. In this study the investigators will first establish a standard operating procedure for measuring pancreas blood flow speed and volume in the pancreas of human subjects. The investigators will then determine 1) whether these pancreas blood flow factors differ between healthy subjects and those who have recently developed type1 diabetes; and 2) how variable measurements are in healthy subjects and subjects that recently developed type1 diabetes, both between subjects and over time. To address these aims the investigators will perform pancreas ultrasound measurements in each subject using an approved injectable 'bubble' contrast agent that allows measurement of pancreas blood flow. The investigators will compare ultrasound measurement with characteristics of the subject's type 1 diabetes, including genetic factors, glucose levels and other circulating factors, as well as other factors that may influence blood flow in the pancreas independent of type1 diabetes. The successful conclusion of this study will indicate whether measuring pancreas blood flow speed/volume will be helpful in monitoring whether type1 diabetes will emerge and thus will allow a large scale study to answer this question.

Read the detailed description

Study Design and Research Methods

Part I:

5 subjects from SOP group Goal: Optimize settings for destruction-replenishment contrast-enhanced ultrasound scan

  1. Subject recruited at the Barbara Davis Center
  2. Subject provides written consent
  3. Review medical history (exclusion if required)
  4. Subject refrains from eating for \~6h prior to measurement
  5. Subject visits University of Colorado Hospital CTRC echo lab
  6. CTRC staff places peripheral intravenous line (PIV)
  7. Research staff collects vital signs, height and weight
  8. Subject received conventional ultrasound scan to locate pancreas tail (by Sonographer, verified by radiologist).
  9. Subject receives DEFINITY dose
  10. Subject receives destruction-replenishment contrast-enhanced ultrasound scan (adjust settings to optimize)
  11. Pause for 30 minutes, allowing subject to stand and move
  12. Repeat steps 9-11 (once).
  13. Subject de-identified.
  14. Analyze data.

Part II:

30 subjects from control group (healthy controls and multiple islet autoantibody positive subjects), 15 subjects from T1D group.

Goal: characterize subject variability and test whether healthy subjects and those with T1D show differing contrast measures

  1. Subject recruited at the Barbara Davis Center
  2. Subject provides written consent
  3. Review medical history (exclusion if required)
  4. Subject refrains from eating for \~6h prior to study
  5. Subject visits University of Colorado Hospital CTRC echo lab
  6. Subject completes questionnaire (family history of diabetes, exclusion criteria)
  7. CTRC staff places peripheral intravenous line (PIV)
  8. Research staff collects vital signs, height and weight
  9. Subject received conventional ultrasound scan to locate pancreas tail (by Sonographer, verified by radiologist).
  10. Subject receives DEFINITY dose
  11. Subject receives destruction-replenishment contrast-enhanced ultrasound scan (under SOP)
  12. Pause for 30 minutes, allowing subject to stand and move
  13. Repeat steps 10-12 (once).
  14. Subject de-identified
  15. Analyze data.

In part I a single repeat measurement may be made to aide in the optimization of data collection. In part II a single repeat measurement is made to assess short-term intra-subject measurement variability.

In part I and part II, a subject will be asked to return on a separate date (within 1 year of the initial scan) for a repeat procedure using an additional DEFINITY delivery method (bolus or infusion, whichever was not given at the initial visit) or if data collection was not of sufficient quality during the first visit.

03

Conditions studied

  • Type1diabetes
  • Insulitis
  • Pancreas Inflamed

Keywords

  • ultrasound
  • tissue perfusion
  • contrast
  • diabetes
  • pancreas
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Group 1 subjects will be healthy subjects who will receive contrast-enhanced ultrasound 'destruction-replenishment' measurements, in order to optimize and establish the standard operating procedure (SOP) for this measurement in the pancreas of human subjects. This SOP will then be applied to Group 2 (healthy subjects and autoantibody positive subjects) and Group 3 (recent onset type1 diabetes) subjects as part of the cross-sectional study. Classification of type 1 diabetes includes meeting ADA criteria for diabetes, within 180 days of diagnosis, and evidence of at least 1 islet-associated autoantibody.

Eligibility criteria

All Participants:

Inclusion Criteria:

  • Male or non-pregnant female age 18-65
  • Ability and willingness of patient to participate fully in all aspects of this clinical study
  • Written obtained and documented

Exclusion Criteria:

  • Excessive body size preventing effective scan of the pancreas as determined by sonographer
  • Evidence of exocrine pancreatic disease, including pancreatitis, cystic fibrosis, pancreatic adenocarcinoma, or neuroendocrine tumor.
  • Subjects who are pregnant or breast-feeding
  • Subjects incapable of giving assent/informed written consent
  • Known or suspected to perflutren
  • Known history or suspected unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias)

Group 2 (control subjects, part II):

Inclusion criteria:

No additional inclusion criteria

Exclusion criteria:

  • Diagnosis of diabetes according to the ADA recommended criteria (blood glucose and will be measured)
  • Use of medications used to control high blood sugar (GLP1R agonists, metformin*, sulfonylureas)

    • *Participants taking metformin will be considered eligible if they are willing/able to stop taking the medication for at least two weeks prior to each scan.
  • Any person who has received immunomodulatory intervention within 3 months of enrollment

Group 3 (T1D subjects, part II)

Inclusion criteria:

  • Diagnosis of diabetes according to the ADA recommended criteria (blood glucose and HbA1c will be measured)
  • Evidence of autoantibodies to at least 1 of the following β-cell autoantigens:

insulin, IA-2, GAD65, ZnT8

  • Presence of insulin autoantibody will only be valid if taken within the first 14 days of diagnosis.

    • Diagnosis of diabetes within 180 days prior to participation in the study

Exclusion criteria:

  • Use of medications used to control high blood sugar (GLP1R agonists, metformin*, sulfonylureas)

    • *Participants taking metformin will be considered eligible if they are willing/able to stop taking the medication for at least two weeks prior to each scan.
  • Any person who has received immunomodulatory intervention within 3 months of enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 1

    SOP (healthy) subjects. Part I of study (optimizing protocol).

    Drug: Definity Suspension for Injection

  • Group 2

    Control (healthy and autoantibody positive) subjects. Part II of study (cross-sectional study)

    Drug: Definity Suspension for Injection

  • Group 3

    T1D subjects. Part II of study (cross-sectional study)

    Drug: Definity Suspension for Injection

Interventions

  • DrugPerflutrenStudies of PerflutrenPerflutren pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    * DEFINITY is administered as per manufactures instructions * 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX * Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial. * Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds. * Following imaging, provide a 10 mL flush of preservative-free saline * Wait at least 30minutes until second dose (if provided).

    Also known as: DEFINITY

06

What researchers measure

Primary outcomes

  1. Primary outcome 1

    Optimized a contrast-enhanced ultrasound 'destruction-replenishment' protocol for imaging pancreas blood flow kinetics in adult human subjects.

    Time frame: End of part I (6 months)

  2. Primary outcome 2

    Comparison of pancreas blood flow kinetics (i.e. 'destruction-replenishment' k2 'reperfusion rate' parameter) between control and T1D subjects.

    Time frame: End of part II (1 year)

  3. Primary outcome 3

    Determining inter-subject variability in pancreas blood flow kinetics (i.e. the 'destruction-replenishment' k2 'reperfusion rate' parameter) among control subjects and among T1D subjects

    Time frame: End of part II (1 year)

  4. Primary outcome 4

    Determining reproducibility in the measurement of pancreas blood flow kinetics (i.e. the 'destruction-replenishment' k2 'reperfusion rate' parameter) within subjects. This will initially focus on short-term intra-subject measurement variability.

    Time frame: End of part II (1 year)

Secondary outcomes

  1. Secondary outcome 1

    Comparison between control and T1D subjects for other parameters resulting from the measurement of pancreas blood flow kinetics (i.e. the 'destruction-replenishment' 'reperfusion amplitude' A, 'destruction efficiency' 1-B and 'pre-destruction signal' parameters).

    Time frame: End of part II (1 year)

  2. Secondary outcome 2

    Determining inter-subject variability among control subjects and among T1D subjects for other parameters resulting from the measurement of pancreas blood flow kinetics (i.e. the 'destruction-replenishment' 'reperfusion amplitude' A, 'destruction efficiency' 1-B and 'pre-destruction signal' parameters).

    Time frame: End of part II (1 year)

  3. Secondary outcome 3

    Correlation of pancreas blood flow kinetics with blood glucose and HbA1c (to test for a link between the measurement and glucose control).

    Time frame: End of part II (1 year)

  4. Secondary outcome 4

    Comparison of pancreas blood flow kinetics with HLA haplotype or whether subject has first-degree relative with T1D (to test for a link between the measurement and T1D genetic risk).

    Time frame: End of part II (1 year)

  5. Secondary outcome 5

    Comparison of pancreas blood flow kinetics with subject BMI, age, heart rate, blood pressure (to test for a link between the measurement and subject characteristics)

    Time frame: End of part II (1 year)

  6. Secondary outcome 6

    Assessment of subject autoantibodies, c-peptide levels (to ensure subjects free of diabetes do not have islet autoimmunity and to ensure subjects with T1D have islet autoimmunity and residual beta cell mass)

    Time frame: End of part II (1 year)

07

Study locations

1 of 1 sites recruiting
  • University of Colorado Anschutz, Barbara Davis Center
    Aurora, Colorado 80045, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Sep 2026, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2022
First posted
Aug 1, 2022
StartActual
Feb 27, 2023
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05482321
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Feb 27, 2023
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
May 6, 2026

Study contacts

Morgan Sooy
Contact
morgan.sooy@cuanschutz.edu
303 724 7526
Hali Broncucia
Contact
hali.broncucia@cuanschutz.edu
303 724 7526
Richard KP Benninger, PhD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion